Researchers at the University of Alabama at Birmingham have shown — for the first time — that established lung fibrosis can be reversed using a drug treatment that targets cell metabolism.
This novel finding, reported in the journal Nature Medicine, is important because, despite significant advances to reveal the pathological mechanisms of persistent fibrosis, effective treatment interventions are lacking.
Pulmonary fibrosis can develop after lung injuries like infections, radiation or chemotherapy, or it can have an unknown cause, as in idiopathic pulmonary fibrosis, or IPF. IPF is a progressive, and ultimately fatal, lung disorder that strikes more than 150,000 patients a year in the United States and more than 5 million worldwide.
In experiments using lung tissues from patients with IPF, mouselung fibroblasts and a murine model of lung fibrosis, a team led by Jaroslaw Zmijewski, Ph.D., and Victor Thannickal, M.D., showed the reversal of lung fibrosis and the underlying cellular mechanisms affected by the drug treatment.
Zmijewski and Thannickal are, respectively, associate professor and professor in the UAB Department of Medicine. Zmijewski serves as research director for the Translational Program in ARDS. Thannickal holds the Ben Vaughan Branscomb Chair of Medicine in Respiratory Disease and is director of the UAB Division of Pulmonary, Allergy and Critical Care Medicine.
|Activation of AMPK in myofibroblasts from lungs of humans with IPF, using the drug metformin or another activator called AICAR, led to lower fibrotic activity. AMPK activation also enhanced the production of new mitochondria, the organelles in cells that produce energy, in the myofibroblasts, and it normalized the cells’ sensitivity to apoptosis.|
Interestingly, the drug that accelerated the resolution of lung fibrosis is metformin, which is a safe and widely used agent for non-insulin-dependent diabetes.
The research focused on AMP-activated protein kinase (AMPK), an enzyme that senses energy state in the cell and regulates metabolism. Zmijewski, Thannickal and colleagues found that AMPK activity was lower in myofibroblast cells within fibrotic regions of human lung tissue from IPF patients. Myofibroblasts deposit extracellular collagen fiber as part of the fibrosis process. These myofibroblasts were metabolically active and were resistant to the programmed cell death called apoptosis, a natural process that removes more than 50 billion damaged or aged cells in adults each day.
Activation of AMPK in myofibroblasts from lungs of humans with IPF, using the drug metformin or another activator called AICAR, led to lower fibrotic activity. AMPK activation also enhanced the production of new mitochondria, the organelles in cells that produce energy, in the myofibroblasts, and it normalized the cells’ sensitivity to apoptosis.
Using a mouse model for lung fibrosis elicited by the anti-cancer drug bleomycin, the research team found metformin treatment, starting three weeks after lung injury and continuing for five weeks, accelerated the resolution of well-established fibrosis. Such resolution was not apparent in AMPK-knockout mice, showing that the effect of metformin was AMPK-dependent.
“Together, our studies support the concept that AMPK may function as a critical metabolic switch in promoting resolution of established fibrosis by shifting the balance from anabolic to catabolic metabolism,” the researchers wrote. “Additionally, we provide proof-of-concept that activation of AMPK by metformin or other pharmacologic agents that activate these pro-resolution pathways may be a useful therapeutic strategy for progressive fibrotic disorders.”
Anabolic metabolism builds up molecules in the cell from smaller units, while catabolic metabolism tears larger molecules into smaller pieces.
Learn more: Metformin reverses established lung fibrosis
The Latest on: Pulmonary fibrosis
via Google News
The Latest on: Pulmonary fibrosis
- Idiopathic Pulmonary Fibrosis Treatment Market By Drug Class, End User, Geography and Forecast 2019 – 2026on November 19, 2019 at 4:25 am
Nov 19, 2019 (Global QYResearch via COMTEX) -- Acumen Research and Consulting has announced the addition of the “Idiopathic Pulmonary Fibrosis Treatment Market” report to their offering. The ...
- Researchers have discovered how the lung disease idiopathic pulmonary fibrosis (IPF) progresseson November 18, 2019 at 9:02 pm
As the researchers have discovered how the lung disease idiopathic pulmonary fibrosis (IPF) progresses, they will now be able to provide a method to discover new treatment targets for the disease. The ...
- Idebenone has preventative and therapeutic effects on pulmonary fibrosis via preferential suppression of fibroblast activityon November 18, 2019 at 3:18 am
Alveolar epithelial injury induced by reactive oxygen species (ROS) and abnormal collagen production by activated fibroblasts (myofibroblasts) is involved in the onset and exacerbation of idiopathic ...
- Yale-led study provides roadmap to discover new treatment for idiopathic pulmonary fibrosison November 15, 2019 at 7:27 pm
A Yale-led collaborative study boosts scientific understanding of how the lung disease idiopathic pulmonary fibrosis (IPF) progresses, providing a roadmap for researchers to discover new treatment ...
- Research points to possible target to treat idiopathic pulmonary fibrosis, or IPFon November 13, 2019 at 1:10 am
Long-held dogma says lung fibrosis in diseases like idiopathic pulmonary fibrosis, or IPF, results from recurrent injury to alveolar epithelium that is followed by dysregulated repair. Research at the ...
- The battle to beat the deadly pulmonary fibrosison November 7, 2019 at 1:49 pm
SAN ANTONIO — Pulmonary fibrosis is a disease that comes with a prognosis of death in just a few years after severe scarring of the lungs. "I couldn't believe what they were telling me that I only had ...
- Study aims to use precision medicine to aid pulmonary fibrosis treatmenton November 5, 2019 at 2:49 pm
The Pulmonary Fibrosis Foundation is starting PRECISIONS, a study intended to transform the diagnosis and treatment of idiopathic pulmonary fibrosis through precision medicine. The study is supported ...
- NIH Awards Major Grant In Pulmonary Fibrosis Researchon November 4, 2019 at 9:44 am
CHICAGO, Nov. 4, 2019 /PRNewswire/ -- The Pulmonary Fibrosis Foundation (PFF) today announced the launch of PRECISIONS, a study that aims to transform the diagnosis and treatment of idiopathic ...
- Pathologic separation of idiopathic pulmonary fibrosis from fibrotic hypersensitivity pneumonitison October 28, 2019 at 9:47 am
Accurate separation of idiopathic pulmonary fibrosis from fibrotic (chronic) hypersensitivity pneumonitis is crucial to patient management, but is frequently a difficult problem. Our objective was to ...
via Bing News